Infectious Disease Diagnostics Market to Reach USD 67.7 Billion by 2036 from USD 25.2 Billion in 2025, Expanding at 9.4% CAGR

The global infectious disease diagnostics market was valued at USD 25.2 Billion in 2025 and is projected to reach USD 67.7 Billion by 2036, expanding at a CAGR of 9.4% from 2026 to 2036. Market growth is primarily driven by the rising prevalence of infectious diseases and increasing demand for rapid, reliable, and accurate diagnostic solutions.

The growing incidence of respiratory, bacterial, viral, fungal, and vector-borne infections is increasing the need for timely pathogen identification and effective disease management. Healthcare providers are increasingly adopting molecular diagnostics, polymerase chain reaction (PCR) testing, multiplex assays, immunodiagnostics, and point-of-care (POC) technologies to accelerate diagnosis and support treatment decisions.

North America dominated the global infectious disease diagnostics market in 2025, accounting for 38.2% of total market revenue. By product and service, reagents, kits & consumables represented the largest segment, accounting for 31.8% of market revenue in 2025. Leading companies include F. Hoffmann-La Roche Ltd., Abbott, Danaher Corporation, bioMérieux, Thermo Fisher Scientific Inc., Siemens Healthineers AG, and QIAGEN N.V.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=43667

Analysts’ Viewpoint on the Global Infectious Disease Diagnostics Market

The global infectious disease diagnostics industry is witnessing steady expansion as the prevalence of infectious diseases increases and healthcare systems place greater emphasis on early and accurate diagnosis. Respiratory diseases, HIV, tuberculosis, sexually transmitted diseases, and other infections continue to create demand for diagnostic technologies capable of identifying pathogens efficiently.

Molecular diagnostics, PCR testing, multiplex assays, rapid diagnostic technologies, and point-of-care solutions are increasingly being adopted to support faster pathogen identification. These technologies can help healthcare professionals make more timely clinical decisions while supporting disease management and infection-control efforts.

However, several factors can constrain market expansion. Advanced diagnostic instruments can involve high costs, while limited reimbursement coverage, stringent regulatory requirements, and shortages of skilled laboratory professionals can affect adoption. Differences in healthcare infrastructure, laboratory capabilities, and access to advanced technologies may also create challenges in developing markets.

At the same time, Asia Pacific, Latin America, and the Middle East & Africa offer opportunities for market expansion as healthcare infrastructure improves and healthcare expenditure increases. Government-led infectious disease control programs and greater awareness of early diagnosis are supporting the adoption of diagnostic technologies in emerging markets.

The market is also shifting toward rapid, decentralized, multiplex, and molecular testing solutions. Greater integration with digital healthcare platforms and laboratory information systems is improving diagnostic workflows. Growing attention toward antimicrobial resistance, genomic surveillance, outbreak preparedness, and emerging pathogens is further encouraging investment in next-generation infectious disease diagnostic technologies.

Infectious Disease Diagnostics Market Introduction

Infectious disease diagnostics encompasses laboratory and clinical testing methods used to detect, identify, and characterize pathogens such as bacteria, viruses, fungi, and parasites. These technologies help healthcare professionals confirm infections, guide treatment decisions, monitor disease progression, and support infection-control and disease-surveillance programs.

The market includes molecular tests, immunoassays, antigen and antibody tests, culture-based techniques, and rapid point-of-care diagnostics. Each testing approach serves different clinical and public health requirements, ranging from routine screening to specialized pathogen identification.

Molecular diagnostic technologies have become increasingly important because of their ability to detect pathogen-specific genetic material. PCR-based testing and other nucleic acid amplification technologies can support sensitive pathogen identification, while multiplex systems can simultaneously detect multiple targets from a single sample.

The growing need for rapid and accurate diagnosis is also encouraging the development of portable and decentralized testing platforms. Point-of-care diagnostics can provide results closer to the patient, reducing dependence on centralized laboratories and supporting faster treatment decisions.

As infectious disease surveillance becomes increasingly important, diagnostic technologies are also being integrated with digital systems, data platforms, and advanced analytics. These developments are expected to strengthen the role of infectious disease diagnostics across hospitals, diagnostic laboratories, public health institutions, and research organizations.

Rising Prevalence of Infectious Diseases Drives Market Growth

The increasing prevalence of infectious diseases worldwide is a major factor contributing to the expansion of the infectious disease diagnostics market. Rising cases of bacterial, viral, fungal, and parasitic infections are increasing the requirement for rapid identification of infections and accurate determination of their underlying pathogens.

Respiratory infections, tuberculosis, HIV, hepatitis, sexually transmitted diseases, gastrointestinal infections, and other infectious conditions place significant demands on healthcare systems. As the number of infected individuals increases, healthcare providers require diagnostic technologies that can support timely confirmation of infections and guide appropriate treatment.

The recurrence and emergence of infectious diseases are further increasing demand for rapid and specific diagnostic technologies. Advanced testing systems enable healthcare professionals to obtain clinically relevant information more quickly than some conventional approaches.

Growing awareness of infectious disease prevention and early diagnosis is also supporting testing volumes. Improvements in healthcare infrastructure and diagnostic facilities in developing countries are expanding access to infectious disease testing.

Government investments in disease surveillance, outbreak preparedness, and infectious disease control programs are contributing to the adoption of advanced diagnostic methods. As healthcare systems strengthen their preparedness for outbreaks and emerging pathogens, demand for diagnostic tests, instruments, reagents, kits, and associated services is expected to increase.

Growing Demand for Early and Accurate Diagnosis Supports Market Expansion

Growing demand for timely and accurate pathogen detection is another key factor supporting infectious disease diagnostics market growth. Early identification of an infection can allow clinicians to make treatment decisions sooner, potentially support disease-control measures, and improve patient management.

The increasing prevalence of respiratory infections, tuberculosis, HIV, hepatitis, sexually transmitted diseases, gastrointestinal infections, and other infectious conditions is strengthening demand for reliable diagnostic solutions.

Healthcare systems are increasingly emphasizing rapid diagnosis to reduce the time between patient presentation and treatment decisions. This is contributing to greater adoption of molecular diagnostics, PCR assays, multiplex testing, immunoassays, rapid antigen tests, and point-of-care technologies.

The growing concern surrounding antimicrobial resistance is also increasing the importance of accurate pathogen identification. Rapid diagnostic technologies can help differentiate between bacterial and viral infections in appropriate clinical settings, supporting more informed antimicrobial-use decisions.

Increased investment in infectious disease monitoring and outbreak preparedness is further supporting testing volumes. At the same time, the shift toward decentralized and near-patient testing is enabling faster access to diagnostic information, particularly in locations where centralized laboratory infrastructure is limited.

Continuous technological development is expected to sustain demand for high-quality infectious disease diagnostic solutions as healthcare providers increasingly prioritize early detection, accurate pathogen identification, and efficient diagnostic workflows.

Growing Adoption of Point-of-Care Diagnostics Creates Market Opportunities

The growing adoption of point-of-care diagnostics is creating significant opportunities for the global infectious disease diagnostics industry. POC testing enables diagnostic procedures to be performed close to patients in hospitals, physicians' offices, urgent care centers, pharmacies, community health centers, and other decentralized healthcare settings.

One of the primary advantages of POC diagnostics is the ability to obtain results within a relatively short period, enabling healthcare professionals to make faster clinical decisions. This is particularly relevant for infectious diseases where timely diagnosis can influence treatment and disease-management strategies.

The need for rapid diagnosis of respiratory infections, sexually transmitted infections, gastrointestinal infections, and other infectious diseases is encouraging healthcare professionals to adopt portable and easy-to-use diagnostic devices.

Molecular POC technologies are also gaining attention because they can enable decentralized testing while retaining the benefits of molecular pathogen detection. Such systems can be particularly valuable in resource-limited and remote settings where access to centralized laboratories may be restricted.

Expansion of healthcare infrastructure in emerging economies is expected to create additional demand for portable infectious disease testing solutions. Increasing concerns about antimicrobial resistance are also strengthening the importance of rapid pathogen detection and timely treatment guidance.

Technological developments in multiplex testing, cartridge-based systems, automation, connectivity, and AI-enabled diagnostic interpretation are further improving the capabilities of POC platforms. As healthcare systems prioritize faster diagnosis, decentralized care, and improved accessibility, point-of-care diagnostics are expected to remain an important growth opportunity.

Reagents, Kits & Consumables Segment Leads Infectious Disease Diagnostics Market

The reagents, kits & consumables segment dominated the global infectious disease diagnostics market in 2025, accounting for approximately 31.8% of total market revenue. The segment's leading position is supported by the recurring nature of diagnostic testing across healthcare facilities, clinical laboratories, research institutions, and other testing environments.

Unlike diagnostic instruments, which are generally purchased less frequently, reagents and consumables require continuous replenishment as testing volumes increase. Diagnostic reagents, test kits, cartridges, test panels, specimen-collection products, and other consumables therefore generate recurring demand for manufacturers and suppliers.

The rising incidence of infectious diseases is increasing the need for routine, screening, and confirmatory testing. The widespread use of molecular diagnostics, PCR-based testing, immunoassays, and multiplex technologies is also increasing consumption of specialized reagents and testing kits.

The shift toward rapid and decentralized testing provides another source of demand. Point-of-care diagnostic platforms depend on dedicated consumables and test cartridges, supporting recurring purchases as testing volumes increase.

Technological advances are also enabling the development of more sophisticated testing kits capable of delivering accurate results and detecting multiple pathogens from a single sample. Continued testing activity, recurring consumable requirements, rising infectious disease prevalence, and technological advancements are expected to support the segment's continued market position.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=43667

Regional Outlook of Infectious Disease Diagnostics Market

North America dominated the global infectious disease diagnostics market in 2025, accounting for approximately 38.2% of total market revenue. The region's leading position is supported by advanced healthcare infrastructure, high diagnostic testing volumes, strong laboratory networks, and widespread adoption of innovative diagnostic technologies.

The region has a developed network of hospitals, clinical laboratories, research centers, and diagnostic organizations that supports the use of molecular diagnostics, immunoassays, PCR testing, and rapid point-of-care technologies.

The U.S. accounts for a substantial share of the regional market due to high healthcare expenditure, an extensive diagnostic laboratory network, and the presence of major diagnostic technology companies. High awareness regarding the importance of timely infectious disease diagnosis is also contributing to demand for advanced testing solutions.

North America has a strong research and development ecosystem that supports the development and commercialization of next-generation diagnostic technologies. Multiplex molecular assays, syndromic testing platforms, automated diagnostic systems, and other advanced solutions are contributing to the evolution of the regional market.

Increasing use of point-of-care and decentralized testing is creating additional demand, particularly across emergency departments, physicians' offices, and outpatient facilities. Ongoing monitoring of new and re-emerging infectious diseases is also supporting diagnostic testing requirements.

The combination of established healthcare infrastructure, high diagnostic demand, technological innovation, research capabilities, and healthcare spending is expected to support North America's continued leadership during the forecast period.

Asia Pacific is also expected to offer significant growth opportunities as healthcare infrastructure expands, healthcare spending increases, and governments strengthen infectious disease control and surveillance programs. Greater awareness of early diagnosis and increasing access to diagnostic technologies are supporting market development across emerging economies in the region.

Analysis of Key Players in Infectious Disease Diagnostics Market

The global infectious disease diagnostics market features several established healthcare and diagnostic technology companies competing across molecular diagnostics, immunodiagnostics, microbiology, PCR, sequencing, point-of-care testing, and laboratory solutions.

Prominent companies include F. Hoffmann-La Roche Ltd., Abbott, Danaher Corporation, bioMérieux, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Becton, Dickinson and Company (BD), QIAGEN N.V., Hologic, Inc., Bio-Rad Laboratories, Inc., DiaSorin S.p.A., QuidelOrtho Corporation, Revvity, Inc., Grifols S.A., and Sysmex Corporation.

Companies are focusing on technological development, product launches, regulatory clearances, molecular testing capabilities, multiplex diagnostics, point-of-care systems, and next-generation pathogen detection technologies.

The competitive environment is also being shaped by increasing demand for faster diagnostic workflows and more comprehensive pathogen detection. Companies are developing platforms capable of detecting multiple pathogens and antimicrobial resistance markers while reducing turnaround time.

Each of the major companies is profiled based on company overview, financial overview, business strategies, product portfolio, business segments, sales footprint, key subsidiaries or distributors, and recent developments.

Key Developments in Infectious Disease Diagnostics Market

In August 2026, QIAGEN announced that the U.S. Food and Drug Administration had cleared the QIAstat-Dx BCID GPF Plus AMR Panel, described as the first QIAstat-Dx bloodstream infection panel to receive FDA clearance. The panel detects 20 gram-positive bacterial and fungal pathogen targets, a broad pan gram-negative target, and 10 genetic antimicrobial resistance markers from positive blood culture samples in approximately one hour.

In July 2026, Roche announced that its Elecsys IGRA TB test had received the CE Mark. The blood-based testing solution is designed to identify tuberculosis infection, also known as latent TB, in routine laboratory settings and can provide results in under 24 hours.

In February 2026, MedGenome announced the launch of MetaSeq, a blood test designed to support detection of bloodstream infections. The technology uses metagenomic next-generation sequencing to analyze microbial cell-free DNA present in the bloodstream, illustrating the expanding application of NGS technologies in infectious disease diagnostics.

These developments demonstrate the industry's ongoing shift toward rapid, comprehensive, molecular, and sequencing-based approaches to pathogen detection.

Infectious Disease Diagnostics Market Segmentation

The global infectious disease diagnostics market can be segmented based on product and service, type of testing, sample type, technology, disease type, end user, and region.

By product and service, the market is divided into reagents, kits & consumables; instruments; and software & services. Reagents, kits & consumables represented the largest segment in 2025, supported by recurring demand associated with infectious disease testing.

Based on type of testing, the market is categorized into laboratory testing and point-of-care (POC) testing. Laboratory testing remains important across hospitals, diagnostic laboratories, and research institutions, while POC testing is gaining attention because of its ability to deliver diagnostic information closer to patients.

By sample type, the market includes blood, serum & plasma; urine; swab samples; stool; and others. Different sample types are used depending on the infectious disease and diagnostic technology being applied.

Based on technology, the market comprises immunodiagnostics, clinical microbiology, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarray, and others.

By disease type, the market is segmented into hepatitis, HIV, tuberculosis, influenza, HPV, hospital-acquired infections, chlamydia, gonorrhea, syphilis, and others.

Based on end user, the market includes hospitals & clinics, diagnostic laboratories, academic & research institutes, public health laboratories, and others. Hospitals and diagnostic laboratories represent important testing environments, while public health laboratories play an important role in surveillance and infectious disease monitoring.

Regionally, the market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Key countries analyzed include the U.S., Canada, Germany, the U.K., France, Italy, Spain, the Netherlands, China, India, Japan, South Korea, Australia, Brazil, Mexico, Argentina, GCC countries, and South Africa.

Infectious Disease Diagnostics Market Outlook

The global infectious disease diagnostics market is expected to witness sustained expansion as the burden of infectious diseases increases and healthcare providers place greater emphasis on rapid and accurate pathogen detection. The market is projected to increase from USD 25.2 Billion in 2025 to USD 67.7 Billion by 2036, representing a CAGR of 9.4% from 2026 to 2036.

Rising demand for early diagnosis is expected to remain a key market driver. Molecular diagnostics, PCR, multiplex testing, immunodiagnostics, sequencing technologies, and rapid POC platforms are expanding the range of available diagnostic solutions.

The growing adoption of point-of-care testing is expected to create additional opportunities by bringing diagnostic capabilities closer to patients and enabling faster clinical decision-making. Portable molecular systems, cartridge-based platforms, connected diagnostics, and AI-enabled technologies can further support decentralized infectious disease testing.

North America is expected to maintain its leading position due to its established healthcare infrastructure, high diagnostic testing volumes, strong research ecosystem, and presence of major industry participants. Meanwhile, Asia Pacific, Latin America, and the Middle East & Africa offer opportunities associated with healthcare infrastructure development, increasing healthcare expenditure, disease-control initiatives, and greater awareness of early diagnosis.

The increasing focus on antimicrobial resistance, genomic surveillance, outbreak preparedness, and emerging pathogens is expected to encourage continued investment in next-generation infectious disease diagnostics. These developments will contribute to the evolution of the market toward faster, more accurate, decentralized, multiplex, and digitally integrated diagnostic solutions through 2036.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=43667<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Autoimmune Disease Diagnostics Market

In Vitro Diagnostics Market

Non-Invasive Cancer Diagnostics Market

Multiplexed Diagnostics Market

Point-of-Care Diagnostics Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com